## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (previously presented). A compound of formula I,

$$R^1$$
 $R^2$ 
 $Y$ — $(CH_2)n$ — $B$ 

wherein

one of R1 and R2 represents a structural fragment of formula la

and the other represents R4;

Z represents O or N(R<sup>5</sup>);

 $R^3$  represents one or more optional substituents selected from OH, halo, cyano, nitro,  $C(O)OR^6$ ,  $C_{1-6}$  alkoxy or  $C_{1-6}$  alkyl, which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group, or  $N(R^7)R^8$ ;

R<sup>4</sup> represents H, OH, halo, cyano, nitro, C(O)OR<sup>6</sup>, C<sub>1-6</sub> alkoxy or C<sub>1-6</sub> alkyl, which

two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group, or  $N(R^7)R^8$ ;

Ar¹ represents phenyl, C<sub>1-3</sub> alkylphenyl, C<sub>1-3</sub> alkyldiphenyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-3</sub>-alkyl-C<sub>3-7</sub>-cycloalkyl, C<sub>1-3</sub>-alkyl-di-C<sub>3-7</sub>-cycloalkyl, naphthyl, C<sub>1-3</sub> alkylnaphthyl, thienyl, imidazolyl or isoxazolyl, all of which may be substituted by one or more substituent selected from OH, halo, cyano, nitro, C(O)OR<sup>6</sup>, C<sub>1-6</sub> alkoxy or C<sub>1-6</sub> alkyl, which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group, or N(R<sup>7</sup>)R<sup>8</sup>;

 $R^5$  represents H,  $C_{1-6}$  alkyl, phenyl or  $C_{1-3}$  alkylphenyl, which three latter groups are optionally substituted and/or terminated by one or more substituent selected from OH, halo, cyano, nitro,  $C(O)OR^9$ ,  $C(O)N(R^{10})R^{11}$ ,  $P(O)(R^{12})R^{13}$ ,  $P(O)(OR^{14})OR^{15}$ ,  $S(O)_2(R^{16})R^{17}$ ,  $S(O)_2N(R^{18})R^{19}$ ,  $C_{1-6}$  alkoxy or  $C_{1-6}$  alkyl, which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group or  $N(R^{20})R^{21}$ ;

Y represents O, S, S(O), S(O)<sub>2</sub> or N( $\mathbb{R}^{22}$ );

 $R^{10}$  and  $R^{11}$  independently represent H,  $OR^{23}$ ,  $C(O)R^{24}$ ,  $OC(O)R^{25}$ ,  $C(O)OR^{26}$ ,  $C_{1-4}$  alkyl, which latter group is optionally substituted and/or terminated by one or more substituent selected from  $C_{1-4}$  alkyl,  $OR^{27}$ ,  $N(R^{28})R^{29}$ ,  $C(O)OR^{30}$ ,  $C(O)N(R^{31})R^{32}$ ,  $P(O)(R^{33})R^{34}$ ,  $P(O)(OR^{35})OR^{36}$  and  $S(O)_2N(R^{37})R^{38}$ ),  $-(CH_2CH_2O-)_pR^{39}$  or, together with the nitrogen atom to which they are attached, form a  $C_{4-7}$  nitrogen-containing, aromatic or non-aromatic, ring which ring may contain a further heteroatom or group as appropriate selected from O, S and  $N(R^{40})$  and may further be substituted by one or more substituent selected from  $C(O)R^{41}$ ,  $C(O)OR^{42}$  or  $C(O)N(R^{43})R^{44}$ ;

 $R^{28}$ ,  $R^{29}$ ,  $R^{30}$ ,  $R^{31}$ ,  $R^{32}$  and  $R^{40}$  independently represent H or  $C_{1-6}$  alkyl, which latter group is optionally substituted and/or terminated by one or more substituent selected from  $C(O)R^{45}$ ,  $C(O)OR^{46}$  or  $C(O)N(R^{47})R^{48}$ ;

at each occurrence,  $R^6$ ,  $R^7$  and  $R^8$  independently represent H or  $C_{1-4}$  alkyl;  $R^9$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ ,  $R^{26}$ ,  $R^{27}$ ,  $R^{33}$ ,  $R^{34}$ ,  $R^{35}$ ,  $R^{36}$ ,  $R^{37}$ ,  $R^{38}$ ,  $R^{39}$ ,  $R^{41}$ ,  $R^{42}$ ,  $R^{43}$ ,  $R^{44}$ ,  $R^{45}$ ,  $R^{46}$ ,  $R^{47}$  and  $R^{48}$  independently represent H or  $C_{1-4}$  alkyl;

n represents 2;

p represents 1, 2, 3, 4, 5 or 6; and

B represents a structural fragment of formula lb, lc, ld or le

wherein

X<sup>1</sup> and X<sup>2</sup> independently represent a single bond or CH<sub>2</sub>; or a pharmaceutically acceptable salt thereof.

2 (original). A compound of formula I, as defined in claim 1, wherein, when B represents a structural fragment of formula lb, Id, Ie or Ic in which latter fragment  $X^1$  and  $X^2$  both represent  $CH_2$ , then n represents 2.

3 (cancelled).

4 (previously presented). A compound of formula I, as defined in claim 1, wherein R<sup>2</sup> represents a structural fragment of formula Ia and R<sup>1</sup> represents R<sup>4</sup>.

5 (previously presented). A compound of formula I, as defined in claim 1, wherein Z represents O or  $N(R^5)$ , in which latter case  $R^5$  represents  $C_{1-6}$  alkyl terminated by  $C(O)N(R^{10})R^{11}$ .

6 (previously presented). A compound of formula I, as defined in claim 1, wherein R³ is not present, or represents methyl, chloro or methoxy.

7 (previously presented). A compound of formula I, as defined in claim 1, wherein Ar<sup>1</sup> represents substituted phenyl.

8 (previously presented). A compound of formula I, as defined in claim 1 wherein Y represents O.

9 (previously presented). A compound of formula I, as defined in claim 1 wherein B represents a structural fragment of formula lb.

10 (original). A compound as claimed in Claim 1 which is:

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl} benzenesulfonamide; benzenesulfonic acid- {3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methyl}phenyl ester; N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2-chlorobenzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2-cyanobenzene-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2-fluorobenzene-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2-(trifluoromethoxy)-benzenesulfonamide;

N-{3-[2-(4- aminoiminomethylphenyl)ethoxy]phenyl}-4-fluorobenzene-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2,5-dimethylbenzene-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-5-chlorothiophene-2-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-1-methylimidazole-3-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-3,5-dimethylisoxazole-4-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl} benzylsulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2,5-dichiorothiophene-3-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenyl}-2-

A CARL STATE OF THE STATE OF TH

chlorobenzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-2-methylphenyl}-benzenesulfonamide;

N-{5-[2-(4-aminoiminomethylphenyl)ethoxy]-2-methylphenyl}benzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenyl} benzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl} benzenesulfonamide;

N-(2-chlorophenyl)sulfonyl-3-[2-(4-aminoiminomethylphenyl) ethoxy]-5-methylphenylaminoacetic acid, ethyl ester;

N-(2-chlorophenyl)sulfonyl-3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylaminoacetamide;

N-(2-chlorophenyl)sulfonyl-3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylaminoacetic acid;

N-(2-chlorophenyl)sulfonyl-2-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}propanoic acid, ethyl ester;

2-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-N-(2-chlorophenyl)sulfonyl-5-methylphenylamino}propanamide;

N-(2-chlorophenyl)sulfonyl-2-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}propanoic acid;

N-(2-chlorophenyl)sulfonyl-2-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}propanoic acid, methyl ester;

N-(2-chlorophenyl)sulfonyl-3-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-

methylphenylamino}butanoic acid, ethyl ester;

3-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-N-(2-chlorophenyl)sulfonyl-5-methylphenylamino}butanamide;

N-(2-chlorophenyl)sulfonyl-3-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}butanoic acid;

N-(2-chlorophenyl)sulfonyl-4-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}pentanoic acid, ethyl ester;

4-{3-[2-(4-aminoiminomethylpheny)ethoxy]-N-(2-chlorophenyl)sulfonyl-5-methylphenylamino}pentanamide;

N-(2-chlorophenyl)sulfonyl-4-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}pentanoic acid;

N-(2-chlorophenyl)sulfonyl-5-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}hexanoic acid, ethyl ester;

5-{3-[2-(4-aminoiminomethylphenyl)ethoxy]- N-(2-chlorophenyl)sulfonyl-5-methylphenyl amino}pentanamide;

N-(2-chlorophenyl)sulfonyl-5-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}hexanoic acid;

N-phenylsulfonyl-3-[2-(4-aminoiminomethylphenyl)ethoxy]phenylaminoacetic acid, ethyl ester;

N-phenylsulfonyl-3-[2-(4- aminoiminomethylphenyl)ethoxy]phenylaminoacetic acid;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-N-(2-hydroxyethyl)-benzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-N-(dimethyloxophosphinylmethyl)-benzenesulfonamide;

2-chlorobenzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenyl ester;

benzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl ester;

2-chloro-4-fluorobenzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)-ethoxy]-5-chlorophenyl ester;

2-chlorobenzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methoxyphenyl ester;

2-chlorobenzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)ethoxy]-5ethylphenyl ester;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}benzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2,4,5-trichlorobenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2-chloro-5-methoxybenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2,5-dibromobenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2,5-dichlorobenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)-ethylthio]-phenyl}-2-methoxy-5-methylbenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2,3,5,6-

tetramethylbemzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-3,4-dimethoxy-benzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-3-bromobenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-3,4-dibromobenzene-sulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2-chloro-4-fluorobenzenesulfonamide; or

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}- 5-bromo-2-methoxybenzenesulfonamide.

11 (original). A compound of formula I, as defined in claim 1, provided that R<sup>1</sup> represents a structural fragment of formula Ia and R<sup>2</sup> represents R<sup>4</sup>.

12 (original). A compound of formula I, as defined in claim 1, provided that Ar<sup>1</sup> represents optionally substituted phenyl.

13 (original). A compound of formula I, as defined in claim 1, provided that  $R^5$  is not substituted by  $P(O)(OR^{14})OR^{15}$ ,  $S(O)_2(R^{16})R^{17}$  or  $S(O)_2N(R^{18})R^{19}$ .

14 (original). A compound of formula I, as defined in claim 1, provided that  $R^{10}$  and/or  $R^{11}$  represent H or unsubstituted  $C_{1-4}$  alkyl.

Marting to the second

15 (original). A compound of formula I, as defined in claim 1, provided that Y represents O, S or N(R<sup>5</sup>).

16 (original). A compound of formula I, as defined in claim 1, provided that B represents a structural fragment of formula lb, lc, or ld.

17 (original). A compound of formula I, as defined in claim 1, provided that R<sup>2</sup> represents a structural fragment of formula Ia and R<sup>1</sup> represents R<sup>4</sup>.

18 (original). A compound of formula I, as defined in claim 1, provided that Ar<sup>1</sup> does not represent optionally substituted phenyl.

19 (original). A compound of formula I, as defined in claim 1, provided that  $R^5$  is substituted by  $P(O)(OR^{14})OR^{15}$ ,  $S(O)_2(R^{16})R^{17}$  or  $S(O)_2N(R^{18})R^{19}$ .

20 (original). A compound of formula I, as defined in claim 1, provided that R<sup>10</sup> and/or R<sup>11</sup> do not represent H or unsubstituted C<sub>1-4</sub> alkyl.

21 (original). A compound of formula I, as defined in claim 1, provided that Y represents S(O) or S(O)<sub>2</sub>.

22 (original). A compound of formula I as defined in claim 1, provided that B

Antonsson Appl. No. 09/839,609 December 20, 2005

represents a structural fragment of formula le.

23 (previously presented). A pharmaceutical formulation including a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

1. 医二氯苯甲酚二甲基胺 电电流设置

24-34 (canceled).